Testosterone enanthate
Testosterone enanthate, long-chain injectable ester
Written by Aaron CuhaReviewed Sep 2026
Also known as: Delatestryl, Xyosted, Test E, Enanthate
The other standard injectable ester, effectively interchangeable with cypionate. It has one thing cypionate does not: an approved weekly auto-injector.
Overview
Enanthate is cypionate's near-twin. A seven-carbon ester instead of an eight-carbon one, a comparable half-life, and no established clinical difference between them. Which one a person receives is usually decided by what the pharmacy stocks.
One practical difference is worth knowing. Enanthate is available in an approved weekly subcutaneous auto-injector, which matters for two reasons. It normalises weekly rather than fortnightly dosing, which is the direction the pharmacokinetics point. And subcutaneous administration is easier to self-deliver than an intramuscular injection into the glute, which is a real barrier for a lot of people.
Everything on the cypionate page about dosing interval applies here unchanged, because it follows from the ester chain length and both esters are short-acting.
Mechanism of action
Testosterone esterified with enanthic acid, a seven-carbon chain, giving an oil-soluble depot that tissue esterases cleave gradually. Once cleaved the hormone is indistinguishable from endogenous testosterone. The slightly shorter chain than cypionate gives a marginally faster release in theory, and the difference has not been shown to matter clinically.
Human evidence
Long approved use with the same pharmacokinetic profile as cypionate, plus an approved weekly subcutaneous auto-injector with its own trial record and its own boxed warning.
- Half-life roughly 7 to 8 days, so the dosing interval matters for the same reasons it does with cypionate.
- An approved weekly subcutaneous auto-injector exists, which makes weekly dosing the labelled schedule rather than an adjustment.
- That auto-injector carries a boxed warning for increases in blood pressure, which is a specific and monitorable risk rather than a general caution.
- No trial establishes a clinical advantage of enanthate over cypionate or the reverse.
- Subcutaneous administration is a genuine practical advantage for self-injection compared with intramuscular.
What this does not tell you: The same gap as cypionate: no randomised comparison of dosing schedules with symptom endpoints. The blood pressure warning applies to the specific auto-injector product and should not be generalised to every enanthate preparation, nor ignored by anyone using that product.
Reading the research record
The dosing interval is where most of the avoidable trouble lives, and the reasoning is simple. Testosterone cypionate and enanthate are short-acting esters. Give a large dose at a long interval and serum testosterone rises well above the target range in the first days and falls toward or below it before the next injection, so the same weekly total produces a very different experience depending on how it is split. A 2026 practice review states the position directly: every-two-week dosing remains convenient and should not be the automatic default for a short-acting injectable, weekly is often reasonable, and where a patient reports symptom cycling, early acne or oily skin, mood or sleep disturbance, breast tenderness, fluid retention, late-cycle fatigue or reduced libido, the problem may be dose timing and peak-to-trough variation rather than an inadequate weekly total. Splitting the same weekly amount across two or three injections flattens that curve.
Two honest limits. This is pharmacokinetic reasoning plus clinical practice, not a randomised trial of split against weekly dosing with symptom endpoints, and no such trial was located. And it changes nothing about the total dose: splitting is a way of delivering the amount you were prescribed more evenly, not a reason to take more. Anyone changing an injection schedule should tell the prescriber, because it also changes when bloodwork should be drawn, and a level measured at the wrong point in the cycle is worse than no level at all.
The evidence, charted
Fig. 1 · evidence composition
1of 2 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2023 and 2026.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Key studies & citations
- Review2026
Individualizing injectable testosterone replacement therapy in primary care: pharmacokinetics, symptom stability, safety monitoring, and injection interval
Treats cypionate and enanthate together as short-acting esters whose dosing interval should be a clinical decision rather than a default. The same reasoning about peak-to-trough variation, symptom cycling and the timing of bloodwork applies to both.
Cureus - Human2023
Cardiovascular safety of testosterone-replacement therapy
TRAVERSE. The cardiovascular safety context for testosterone replacement generally, using a transdermal gel titrated to a defined range.
New England Journal of Medicine
Frequently asked questions
Is enanthate different from cypionate?
Not in any way that has been shown to matter clinically. The ester chains differ by one carbon and the half-lives are close. The practical differences are what your pharmacy stocks, the carrier oil, and that enanthate has an approved weekly subcutaneous auto-injector.
Is subcutaneous as good as intramuscular?
For enanthate there is an approved subcutaneous product, so the route is not improvised. It is easier to self-administer and generally better tolerated than an intramuscular glute injection. That product carries a boxed warning for blood pressure increases, so it needs monitoring.
Does the same split-dosing reasoning apply?
Yes, unchanged. It follows from the ester chain length rather than from anything specific to cypionate, and both are short-acting esters with comparable half-lives.